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1. Introduction
Recent  advances  in  Regenerative  Biology  and  Regenerative  Medicine  are  impressive
and  in  the  last  years  the  scientific  community  has  witnessed  the  emergence  of  many
new  concepts  and  discoveries.  Until  a  few  years  ago,  biological  tissues  were  regarded
as  unable  of  extensive  regeneration,  but  nowadays  organs  and  tissues  like  the  brain,
spinal  cord  or  cardiac  muscles  appear  as  capable  to  be  reconstructed,  based  on  “stem
cells” [1].
Stem cell research has sparked an international effort due to the variety of possible uses
in clinical procedures to treat diseases and improve health and life expectancy. Stem cell
research has crossed a century journey and has evolved greatly even in its  own defini‐
tion.  In  1967,  Lajtha  defined  that  adult  stem cells  could  only  be  found in  regenerative
organs, such as blood, intestine, cartilage, bone and skin. Nowadays, these cells are con‐
sidered to exist  even in tissues with no commitment to regeneration such as the central
nervous system [1, 2].
© 2013 Gärtner et al.; licensee InTech. This is an open access article distributed under the terms of the
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2. Stem cells
Stem cells  are  undifferentiated cells,  with endless  self-renewal  sustained proliferation in
vitro  and  multilineage  differentiation  capacity  [3].  This  in  vitro  multilineage  differentia‐
tion capacity has targeted these cells with extreme importance for use in tissue and cell-
based therapies.
The first stem cell appearance is in the early zygotic cells, which are totipotent and give rise
to the blastocyst. They are capable to differentiate into all cell and tissue types. With differ‐
entiation, cells become less capable of self-renewal and differentiation in other cell type be‐
comes more limited [1]. Stem cells can be loosely classified into 3 broad categories based on
their growth behavior and isolation time during ontogenesis: embryonic, fetal and adult.
Embryonic stem cells (ESCs) were first observed in a pre-implantation embryo by Bongso
and colleagues in 1994 [4]. Since then, many cell lines and a multiplicity of tissues have been
successfully derived from ESCs and tested in several animal disease models [5-7]. Neverthe‐
less, post-transplantation immune-rejection has been a major problem. Many studies are be‐
ing conducted to avoid this major issue. This could be resolved by personalizing tissues
through somatic nuclear transfer (NT) or induced pluripotent stem cells (iPSC) techniques
[8], but the teratoma development in animals is still a concern and a serious problem [9]. In
order to overcome the limitations placed by ESCs and iPSCs, a variety of adult stem cell
populations have been recently isolated and characterized for their potential clinical use.
While still multipotent, adult stem cells have long been considered restricted, giving rise on‐
ly to progeny of their resident tissues [9]. In vivo, adult stem cells exist in a quiescent state,
located in almost all tissues, until mediators activate them to restore and repair injured tis‐
sues. These cells are surrounded by mature cells that have reached the end line in terms of
differentiation and proliferation [10]. Stem cell research focuses on the development of cell
and tissue differentiation, so as characterization techniques, for tissue and cell identification
with marker patterns. Such protocols are essential for regenerative therapies [11].
 
2.1. Mesenchymal stem cells
The development of cell-based therapies for cartilage [12] and skin [13] reconstruction
marks the beginning of a new age in tissue regeneration. Mesenchymal stem cells (MSCs)
have become one of the most interesting targets for tissue regeneration due to their high
plasticity, proliferative and differentiation capacity together with their attractive immuno‐
suppressive properties. MSCs present low immunogenicity and high immunosuppressive
properties due to a decreased or even absence of Human Leucocyte Antigen (HLA) class II
expression [14]. Research in this field has brought exciting promises in many disorders and
therefore in tissue regeneration. Currently the differentiation potential of MSCs in multiline‐
age end-stage cells is already proven, and their potential for treatment of cardiovascular
[15], neurological [16], musculoskeletal [17, 18], and cutaneous [19] diseases is now well es‐
tablished. Fibroblast colony-forming units or marrow stromal cells, currently named MSCs,
Advances in Biomaterials Science and Biomedical Applications466
were first isolated in 1968 from rat bone marrow [20]. These cells were clonogenic, formed
colonies when cultured, and were able to differentiate in vitro into bone, cartilage, adipose
tissue, tendon, muscle and fibrous tissue. Since then many other tissues have been used to
isolate these cells. MSCs can be obtained from many different tissues, including bone mar‐
row, adipose tissue, skeletal muscle, umbilical cord matrix and blood, placental tissue, amni‐
otic fluid, synovial membranes, dental pulp, fetal blood, liver, and lung [21]. The concept of
MSCs is based on their ability to differentiate into a variety of mesodermal tissues and was
first proposed by Caplan in 1991 [22] and further validated by additional research in 1999
[23]. Due to the many different methods and approaches used for MSCs culture, the Mesen‐
chymal and Tissue Stem Cell Committee, of the International Society for Cellular Therapy
(ISCT), recommended several standards do define MSCs [24]. Therefore, MSCs are defined
as presenting: i) plastic adherent ability; ii) absence of definitive hematopoietic lineage
markers, such as CD45, CD34, CD14, CD11b, CD79α, CD19 and class-II Major Histocompati‐
bility Complex (MHC) molecules, specially HLA-DR; and expression of nonspecific markers
CD105, CD90 and CD73 iii) ability to differentiate into mesodermal lineage cells, osteocytes,
chondrocytes and adipocytes. Along with mesodermal differentiation, it has been demon‐
strated the capacity of MSCs to differentiate into ectodermal cell lines, as neurons [25, 26],
keratocytes [27] and keratinocytes [28], so as endodermal cell line, like hepatocytes [29, 30]
and pancreatic β-cells [31]. Moreover, they also possess anti-inflammatory and immunomo‐
dulation properties and trophic effects [32, 33]. Increasing evidence now demonstrates that
the therapeutic effects of MSCs do not lay only on the ability to repair damage tissue, but
also on the capacity of modulating surrounding environment, by secretion of multiple fac‐
tors and activation of endogenous progenitor cells [34, 35]. Compared with ESCs and other
tissue specific stem cells, MSCs are more advantageous. Moreover some studies have dem‐
onstrated that MSCs have a higher chromosomal stability and lower tendency to form tu‐
mors and teratomas, compared to other stem cells [36, 37].
Although they present similar biological characteristics, it cannot be ignored the existing of
some disparities, as differences in, expansion potential under same culture conditions and
age-related functional properties [38]. Compared to ESCs, MSCs isolated from the umbili‐
cal cord matrix (Wharton’s jelly) have many advantages, such as shorter population dou‐
bling time, easy culture in plastic flasks, good tolerance towards the immune system, so
that transplantation into non-immunesuppressed animals does not induce acute rejection, an‐
ticancer properties, [9] and most important absence of tumorigenic activity. As well as ESCs,
these cells are originated from the inner cell mass of the blastocyst but with a major differ‐
ence: they do not raise ethical controversies, since they are collected from tissues usually dis‐
carded at birth [39].
 
2.1.1. MSCs sources and validation of transport and processing protocols
Bone marrow, adipose tissue, umbilical cord blood and umbilical cord matrix have been
considered the main sources of MSCs for tissue engineering purposes. Among these sources,
bone marrow represents the main source of MSCs for cell therapy. However, the prolifera‐
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tive capacity [40-43], differentiation potential and clonal expandability [44] of MSCs derived
from bone marrow decrease significantly with age, gender and seeding density, and the
number of cells per marrow aspirate is usually quite low [3, 45]. It is still a mystery if MSCs
ageing is due to factors intrinsic or extrinsic to the cells. Many possible reasons have been
described in an attempt to explain MSCs ageing. Possible extrinsic factors include: reduced
synthesis of proteoglycans and glycosaminoglycans reducing proliferation and viability [46],
and production of glycosylated end products, inducing apoptosis and reactive oxygen spe‐
cies [47]. Intrinsic factors causing MSCs ageing might include: cell senescence-associated β-
galactosidase and higher expression of p53 and pathway genes p21 and BAX, resulting in
blunted proliferation potential [43]. Regarding seeding density, many authors suggest that
lower seeding densities induce faster proliferation rates [48, 49]. This has been explained by
contact inhibition in higher seeding densities [49], and higher nutrient availability per cell in
lower seeding densities [49]. Use of bone marrow MSCs has disadvantages; donors are sub‐
mitted to invasive harvest of bone marrow. This raises the need to find alternative sources of
MSCs for autologous and allogenic use. Candidate tissue sources should provide MSCs dis‐
playing high proliferative and differentiation potency [50].
Extra-embryonic tissues are a good alternative to adult donor. This tissues, such as, amn‐
ion, microvillus, Wharton’s jelly and umbilical cord perivascular cells, are routinely discard‐
ed at child-birth, so little ethical and religious controversy attends the harvesting of the
resident stem cell populations. The comparatively large volume of extra-embryonic tis‐
sues increases the chance of isolating suitable amounts of stem cells, despite the complex
and expensive procedures needed for their isolation. Some protocols use enzymatic diges‐
tion while others use enzyme-free tissue explant methods that require longer culture time
[51]. There are also MSCs in cord blood (CB), but many studies report low frequency of
these cells and unsuccessful isolation. However, Zhang and colleagues were able to iso‐
late MSCs from CB with a 90% successful rate when CB volume was ≥ 90ml and a trans‐
port time until storage was ≤ 2 hours [51].
In recent years, MSCs derived from umbilical cord matrix Wharton’s jelly, have attracted
much interest. Wharton’s jelly is a mature mucous tissue and the main component of the
umbilical cord, connecting the umbilical vessels to the amniotic epithelium. Umbilical cord
derives from extra-embryonic or embryonic mesoderm; at birth it weighs about 40g and
measures approximately 30-65cm in length and 1.5cm in width [52]. Anyway, individual
differences are observed within newborn babies. Fong and colleagues characterized Whar‐
ton’s Jelly stem cells and found the presence of both embryonic and MSCs, targeting this
source as unique and of valuable use for clinical applications. MSCs from the Wharton’s jel‐
ly can be cultured with little or even no major loss trough at least 50 passages [53].
CB and more recently, umbilical cord tissue (UCT) have been stored cryopreserved in pri‐
vate and public cord blood and tissue banks worldwide in order to obtain hematopoietic
and MSCs and, although guidelines exist (Netcord – Foundation for the Accreditation of
Cellular Therapy), standardized procedures for CB and UCT transport from the hospital /
clinic to the laboratory, storage, processing, cryopreservation and thawing are still awaited.
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These may be critical in order to obtain higher viable stem cells number after thawing and
limit microbiological contamination.
Our research group focused in determining whether UCT storage and transport from the
hospital / clinical to the laboratory at room temperature (RT) or refrigerated (4-6°C) and im‐
mersed in several sterile saline solutions affects the UCT integrity in order to be cryopre‐
served. The umbilical cord contains two arteries and one vein, which are surrounded by
mucoid connective tissue, and this is called the Wharton’s jelly. The cord is covered by an
epithelium derived from the enveloping amnion. The interlaced collagen fibers and small,
woven bundles are arranged to form a continuous soft skeleton that encases the umbilical
vessels. In the Wharton’s jelly, the most abundant glycosaminoglycan is hyaluronic acid,
which forms a hydrated gel around the fibroblasts and collagen fibrils and maintains the tis‐
sue architecture of the umbilical cord by protecting it from pressure [54].
One centimeter-long fragments of umbilical cords (N = 12) were collected from healthy do‐
nors after written informed consent and following validated procedures according to the
clinical and technical guidelines of the Private Bank Biosckin, Molecular and Cell Therapies,
SA (authorized for processing and cryopreserving CB and UCT units by the Portuguese
Minister of Health, ASST – Autoridade para os Serviços de Sangue e de Transplantação).
The 1 cm fragments were immersed for 168 hours in 4 different sterile saline solutions at RT
(22-24°C) and refrigerated (4-6°C): NaCl 0.9% (Labesfal, Portugal), AOSEPT®-PLUS (Ciba
Vision, Portugal), Dulbecco’s Phosphate-Buffered Saline without calcium, magnesium and
phenol red (DPBS, Gibco, Invitrogen, Portugal) and Hank’s Balanced Salt Solution (HBSS,
Gibco, Invitrogen, Portugal). The preservative-free, aqueous AOSEPT® PLUS solution con‐
tains hydrogen peroxide 3%, phosphonic acid (stabiliser), sodium chloride, phosphate (buf‐
fer system), and poloxamer (surfactant), and is usually used to transport and wash contact
lenses. After 168 hours, the fragments were collected in 4% of paraformaldehyde and proc‐
essed for light microscopy. The samples were fixed in 4% paraformaldehyde for 4 hours and
then washed and conserved in phosphate buffer saline (PBS) until embedding. The speci‐
mens were dehydrated and embedded in paraffin and cut at 10 μm perpendicular to the
main umbilical cord axis. For light microscope analysis, sections were stained with haema‐
toxylin and eosin (HE) and observed with a Leica DM400 microscope equipped with a Leica
DFC320 digital camera. The UCT integrity was evaluated through the following parameters:
i. detachment of vessels and retraction of vascular structures;
ii. loss of detail and integrity of the endothelium;
iii. connective tissue degradation;
iv. autolysis of fat (impossible to assess, due to histological technique); and
v. loss of detail and integrity of the mesothelium.
It was concluded that the best transport solutions were HBSS or DPBS at a temperature of
4-6°C since those maintained the histological structure of UC evaluated through those 5 pa‐
rameters previously referred (Figure 1 and Figure 2).
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Figure 1. Cross section of an umbilical cord transported immersed in DPBS at the refrigerated temperature of 4-6°C.
Samples were stained with haematoxylin and eosin (HE). Magnification: 10X.
Figure 2. Cross section of an umbilical cord transported immersed in DPBS at the refrigerated temperature of 4-6°C.
Samples were stained with haematoxylin and eosin (HE). The UCT integrity was quality evaluated through the follow‐
ing parameters: i) detachment of vessels and retraction of vascular structures; ii) loss of detail and integrity of the en‐
dothelium; iii) connective tissue degradation; iv) autolysis of fat (impossible to assess, due to histological technique);
and v) loss of detail and integrity of the mesothelium. Magnification: 40X.
As a matter of fact, the UC immersed for 168 hours in DPBS and HBSS at refrigerated tem‐
perature presented integrity of the histological structure comparable to a UC collected and
processed for histological analysis immediately after birth (Figure 3). With DPBS, a slight re‐
traction of the vessels was noted, which is advantageous since the vessels are stripped and
discarded before cryopreservation of the UCT. It was concluded that the transport of the UC
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from the hospital / clinic to the cryopreservation laboratory should be performed with the
UC immersed in DPBS or HBSS at refrigerated temperatures.
Figure 3. Cross section of an umbilical cord collected and processed for histological analysis immediately after birth under
optimal conditions according to Netcord guidelines. Stained with haematoxylin and eosin (HE). Magnification: 40X.
The isolation and culture of MSCs from the Wharton’s jelly was performed by our research
group in order to obtain undifferentiated MSCs and in vitro differentiated into neural-like
cells to be tested in axonotmesis and neurotmesis lesions of the rat sciatic nerve. The isola‐
tion has been performed by enzyme-free tissue explant and enzymatic isolation. Despite our
standard approaches, we are aware that there are still significant variations that exist be‐
tween laboratory protocols, which must be taken into account when comparing results us‐
ing other methodologies. There is a wide range of individual differences among donor
tissues also and our protocols usually use 15 - 20 cm of UC. While most UC samples will
provide a reasonable number of MSCs using the provided protocols, some samples may re‐
sult in sub-optimal cell isolation and expansion. The reasons behind this phenomenon still
remain to be clarified, but as we have previously mentioned, the temperature and the time
of transport from the hospital / clinic to the cryopreservation laboratory is crucial.
Irrespective of the specific protocol, the washing procedure of the umbilical cord fragments is
crucial in order to avoid microbiological contamination of the cultures. After obtaining the writ‐
ten informed consent from the parents, fresh human umbilical cords are obtained after birth
and collected in HBSS or DPBS at 4-6°C, as it was previously described. After washing the um‐
bilical cord unit 4 times in rising DPBS, disinfection is performed in 75% ethanol for 30 sec‐
onds. Finally, and before the dissection step, umbilical cord unit is washed in DPBS. The vessels
are usually stripped with UC unit still immersed in DPBS. Once washing step in MSCs isola‐
tion and culture is essential to achieve good UCT units for cryopreservation and future clini‐
cal use, washing protocol was validated. DPBS from the first washing step (used immediately
after collection for transportation of the unit to the laboratory – washing step 1 solution) and
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DPBS used in washing step after disinfection in 75% ethanol (washing step 6 solution) from 14
umbilical cord units (N = 14) collected from healthy donors and transported from the hospital/
clinic at 4-6°C in less than 96 hours were tested for microbiological contamination using BacT/
ALERT® (bioMérieux). Each unit was tested for aerobic and anaerobic microorganisms and
fungi using 10 ml of the washing step 1 solution and washing step 6 solution which were asepti‐
cally introduced into the BacT/ALERT® testing flasks. All procedures were performed in a lam‐
inar flow tissue culture hood under sterile conditions. All the units that presented microbial
contamination in DPBS obtained from the first washing step (washing step 1 solution) present‐
ed no contamination in the analysis performed to DPBS from the last washing step immediate‐
ly performed before MSCs isolation or UCT cryopreservation (washing step 6 solution). The
following microorganisms were identified in the DPBS solution from the first washing step:
Staphylococcus lugdunensis (N = 2); Staphylococcus epidermidis (N = 1); Staphylococcus coagulase
(N = 2); Escherichia coli (N = 4); Enterococcus faecalis (N = 1); and Streptococcus sanguinis (N = 1).
The DPBS solution from the first washing step (washing step 1 solution) from 3 units was neg‐
ative for microbial contamination (N = 3). These results permitted us to conclude that the wash‐
ing protocol was 100% efficient in what concerns microbiological elimination (including aerobic
and anaerobic bacteria, yeast and fungi).
Once the transport and washing protocols were validated, it was important to isolate and
expand in vitro the MSCs from the UCT units for pre-clinical trials.
Figure 4. MSCs isolated from Wharton’s jelly using the “enzymatic protocol” exhibiting a mesenchymal-like shape
with a flat polygonal morphology. Magnification: 100x.
In the “enzymatic procedure” we use collagenase type I (Sigma-Aldrich). With the written
informed consent from the parents, fresh human umbilical cords were obtained after birth
and stored in HBSS (Gibco, Invitrogen, Portugal) for 1–48 hours before tissue processing to
obtain MSCs. After removal of blood vessels, the mesenchymal tissue is scraped off from the
Wharton’s jelly with a scalpel and centrifuged at 250 g for 5 minutes at room temperature
and the pellet is washed with serum-free Dulbecco’s modified Eagle’s medium (DMEM,
Advances in Biomaterials Science and Biomedical Applications472
Gibco, Invitrogen, Portugal). Next, the cells are centrifuged at 250 g for 5 minutes at room
temperature and then treated with collagenase (2 mg/ml) for 16 hours at 37°C,washed, and
treated with 2.5% trypsin-EDTA solution (Sigma-Aldrich) for 30 minutes at 37°C with agita‐
tion. Finally, the cells are washed and cultured in DMEM (Gibco, Invitrogen, Portugal) sup‐
plemented with 10% fetal bovine serum (FBS), glucose (4.5 g/l), 1% (w/v) penicillin and
streptomycin (Sigma), and 2.5 mg/ml amphotericin B (Sigma) in 5% CO2 in a 37°C incubator
(Nuaire). Around 2 × 105 cells are plated into each T75 flask in 10 ml culture medium. Cells
are allowed to attach and grow for 3 days. To remove the non-adherent cells or fragments,
the flasks are gently washed using pre-warmed DPBS after which 10 ml of pre-warmed cul‐
ture medium is added. The culture medium is changed every third day (or twice per week).
Confluence (80-90%) is normally reached at day 12–16, and the cells are removed with pre-
warmed trypsin-EDTA solution (4 ml per flask), for 10 min at 37°C. The cells are plated onto
poly-l-lysine coated glass coverslips (in 6- or 24-well tissue culture plates) or on biomaterials
used in the nerve reconstruction. Normally, 5000 cells/cm2 are plated on the coverslips or on
the membranes (Figure 4).
In our “enzyme-free tissue explant protocol” for isolation of MSCs, enzymatic digestion is not
employed. The mesenchymal tissue (Wharton’s jelly) is diced into cubes of about 0.5 cm3 and
the remaining vessels are removed by dissection. Using a sterile scalp, the cubes are diced in
1-2 mm fragments and transferred to a Petri dish pre-coated with poly-l-lysine (Sigma) with
Mesenchymal Stem Cell Medium (PromoCell, C-28010) supplemented with 1% (w/v) penicil‐
lin and streptomycin (Sigma), and 2.5 mg/ml amphotericin B (Sigma) and cultured in 5% CO2
in a 37°C incubator (Nuaire). Some tissue fragments will allow cell migration from the ex‐
plants in 3-4 days incubation. Confluence is normally obtained 15-21 days after.
The laboratory’s processing and cryopreservation protocols of the UCT units following the
technical procedures of Biosckin, Molecular and Cell Therapies S.A. (BSK.LCV.PT.7) were
validated for the ability of isolating and expanding in vitro MSCs after cryopreserved UCT
thawing. The protocols of processing and cryopreservation of the UCT are protected by a
Confidentiality Agreement between Biosckin, Molecular and Cell Therapies S.A. and all the
involved researchers. Briefly, the UCT collected from healthy donors (N = 60), and according
to Netcord guidelines and following the Portuguese law 12/2009 (Diário da República, lei
12/2009 de 26 de Março de 2009) is diced into cubes of about 0.5 cm3 and the remaining vessels
are removed by dissection. In order to ensure the viability of the UCT after parturition and
limit the microbiological contamination of the samples, the umbilical cords were transported
from the hospital / clinic to the laboratory at refrigerated temperatures monitored by a data‐
lloger in less than 72 hours. The UCT units from 15-20 centimeters-long umbilical cords and
after the blood vessels dissection are treated and processed for cryopreservation using a cry‐
oprotective solution (freezing medium). The UCT units are transferred to a computer-con‐
trolled slow rate freezer (Sylab, Consensus, Portugal) and a nine-step freezing program is
used to set up the time, temperature, and rates specifically optimized for the human umbili‐
cal cord-MSCs cooling. To thaw frozen cells, the cryovials are transferred directly to a 37°C
water bath. Upon thawing in less than a minute, the cell suspension is centrifuged at 150 × g
for 10 min, and the supernatant is gently removed and the cell pellet is resuspended in cul‐
ture medium. It was possible to obtain MSCs in culture from 52 out of 60 thawed UCT units.
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In some UCT cryopreserved units (N = 8) it was not possible to isolate MSCs due to increase
number of erythrocytes’ lysis or microbiological contamination during cell culture. The
MSCs morphology was observed in an inverted microscope (Zeiss, Germany) at different
points of expansion. The MSCs exhibited a mesenchymal-like shape with a flat and polygo‐
nal morphology. The MSCs obtained were characterized by flow cytometry (FACSCalibur®,
BD Biosciences) analysis for a comprehensive panel of markers, such as PECAM (CD31),
HCAM (CD44), CD45, and Endoglin (CD105). In the presence of neurogenic medium, the
MSCs were able to, became exceedingly long and there was a formation of typical neuro‐
glial-like cells with multi-branches and secondary branches. These results permitted to con‐
clude that the processing and cooling protocols used for UCT units’ cryopreservation were
adequate to preserve the UCT viability since it was possible to isolate and expand MSCs af‐
ter appropriate thaw and in presence of adequate cell culture conditions.
An established and ready-to-use Human MSC cell line was also employed for promoting ax‐
onotmesis and neurotmesis lesions regeneration. Human MSCs from Wharton’s jelly umbili‐
cal cord were purchased from PromoCell GmbH (C-12971, lot-number: 8082606.7).
Cryopreservated cells are cultured and maintained in a humidified atmosphere with 5%
CO2 at 37°C. Mesenchymal Stem Cell Medium (PromoCell, C-28010) is replaced every 48
hours. At 80-90% confluence, cells are harvested with 0.25% trypsin with EDTA (Gibco) and
passed into a new flask for further expansion. MSCs at a concentration of 2500 cells/ml are
cultured on poli-D-lysine coverslips (Sigma) or on biomaterials membranes and after 24
hours cells exhibit 30-40% confluence. Differentiation into neuroglial-like cells is induced
with MSC neurogenic medium (Promocell, C-28015). Medium is normally replaced every 24
hours during 3 days. The formation of neuroglial-like cells can be observed after 24 hours in
an inverted microscope (Zeiss, Germany) (Figure 5 and Figure 6).
Figure 5. MSC cell line from Wharton’s jelly (PromoCell) exhibiting a mesenchymal-like shape with a flat polygonal
morphology. Magnification: 100x.
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Figure 6. MSC cell line from Wharton’s jelly (PromoCell) after 72h of incubation in neurogenic medium. The cells be‐
came exceedingly long and there is a formation of typical neuroglial-like cells with multibranches. Magnification: 100x.
This established human MSC cell line is preferred for in vivo testing in rats, since the number
of MSCs obtained is higher in a shorter culture time, it is not dependent on donors availabil‐
ity and ethic committee authorization, and the protocol is much less time consuming which
is advantageous for pre-clinical trials with a large number of experimental animals. As a
matter of fact, there is no need of administrating immunosuppressive treatment to the ex‐
perimental animals during the entire healing period after the surgical procedure. The phe‐
notype of MSCs was assessed by PromoCell. Rigid quality control tests are performed for
each lot of PromoCell MSCs isolated from Wharton’s jelly of umbilical cord. MSCs are tested
for cell morphology, adherence rate and viability. Furthermore, each cell lot is characterized
by flow cytometry analysis for a comprehensive panel of markers.
The MSCs isolated with the two protocols described (from fresh and the cryopreserved UCT
units) and from the established Promocell cell line exhibited a mesenchymal-like shape with
a flat and polygonal morphology. During expansion the cells became long spindle-shaped
and colonized the whole culturing surface. After 96 hours of culture in neurogenic medium,
cells changed in morphology. The cells became exceedingly long and there was a formation
of typical neuroglial-like cells with multi-branches and secondary branches. Giemsa-stained
cells of differentiated MSC cell line at passage 5 were analyzed for cytogenetic characteriza‐
tion. However, no metaphases were found, therefore the karyotype could not be established.
The karyotype of undifferentiated HMSCs was determined previously and no structural al‐
terations were found demonstrating absence of neoplastic characteristics in these cells, as
well as chromosomal stability to the cell culture procedures [55, 56]. The differentiated
MSCs karyotype could not be established, since no dividing cells were obtained at passage
5, which can be in agreement with the degree of differentiation. The karyotype analysis of
undifferentiated MSCs previously determined, excluded the presence of neoplastic cells,
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thus supporting the suitability of our cell culture and differentiation procedures. This con‐
cern also resulted from our previous experience with N1E-115 neoplastic cell line and the
negative results we obtained in the treatment of axonotmesis and neurotmesis injuries
[57-59]. Nevertheless, undifferentiated MSCs from the Wharton’s jelly culture (obtained
from either protocol or from the Promocell cell line) showed normal morphology when in‐
spected with an inverted microscope (Figure 7).
The differentiation was tested based on the expression of typical neuronal markers such as
GFAP, GAP-43 and NeuN by neural-like cells attained from MSCs. Undifferentiated MSCs
were negatively labeled to GFAP, GAP-43 and NeuN. After 96 hours of differentiation the
attained cells were positively stained for glial protein GFAP and for the growth-associated
protein GAP-43. All nucleus of neural-like cells were also labeled with the neuron specific
nuclear protein called NeuN showing that differentiation of MSCs in neural-like cells was
successfully achieved for MSCs obtained from UCT (fresh and cryopreserved) and for the
Promocell MSC cell line (Figure 8) [55].
2.1.2. Differentiation into neuroglial-like cells
MSCs express nestin, a maker for neural and other stem cells [60, 61] and can be differentiat‐
ed in adipose tissue, bone, cartilage, skeletal muscle cells, cardiomyocyte-like cells, and neu‐
roglial-like cells [54, 55, 60, 62], presenting great potential to biomedical engineering
applications. These cells fit into the category of primitive stromal cells and because they are
abundant and inexpensive, they might be very useful for regenerative medicine and biotech‐
nology applications.
By employing neuron-conditioned media, sonic hedgehog and fibroblast growth factor 8,
MSCs isolated from the Wharton’s jelly can be induced toward dopaminergic neurons.
These cells have been transplanted into hemiparkinsonian rats where they prevented the
progressive degeneration/behavioral deterioration seen in these rats [63]. Rat MSCs isolated
from the Wharton’s jelly when transplanted into brains of rats with global cerebral ischemia
significantly reduced neuronal loss, apparently due to a rescue phenomenon [64]. Neuronal
differentiation of human MSCs could also provide cells to replace neurons lost due to neuro‐
degenerative diseases. Recent studies showed that transplanted MSCs-derived neurons be‐
come electrophysiologically integrated within the host neural tissue [65]. However, all these
therapeutic applications need uniform and reproducible regulation.
A consequence of cell metabolism during in vitro expansion is that culture conditions are
constantly changing. The comprehension and optimization of the expansion and differentia‐
tion process will contribute to maximization of cell yield, reduced need of cell culture, and a
decrease in total processing costs [66, 67]. Elucidation of regulatory mechanisms of MSCs
differentiation will allow optimization of in vitro culture and their clinical use in the treat‐
ment of neural-related diseases. Research is being performed to optimize expansion process
parameters in order to grow MSCs in a controlled, reproducible, and cost-effective way [68].
Metabolism is certainly one of these parameters.
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3. Regeneration and in vivo testing
With the world wide global increase in life expectancy, a variety of disabling diseases with
large impact on human population are arising. This includes cardiovascular, neurological,
musculoskeletal, and malignancies. Therefore, it is imperative that new and more effective
treatment methods are developed to correct for these changes. Further research with experi‐
mental animal systems is required to translate to in vivo cell-based therapy that has been
extensively investigated in vitro [1]. Stem cell biology is probably the golden key for cell
therapies and regenerative medicine. Regeneration is the physical process where remaining
tissues organize themselves to replace missing or injured tissues in vivo [39].
It has been speculated that once MSCs have the potential to differentiate into several tissues,
they might be responsible for turnover and maintenance of adult tissues, just like hemato‐
poietic stem cells have this role in blood cells [69]. First, it was believed that after injection of
MSCs, these were able to migrate to the damaged site and to differentiate into ones with the
appropriate function for repairing, so MSCs could mediate tissue repair through there mul‐
tilineage capacity replacing damaged cells. Subsequent studies have suggested that the
mechanism used by MSCs for tissue repairing is not really this way. This new idea was rein‐
forced by the confirmation that this cells homed to damaged site, particularly to spots of hy‐
poxia, inflammation and apoptosis [70, 71].
Recent studies demonstrated that transplanted MSCs modified the surrounding tissue mi‐
croenvironment, promoting repair with functional improvement by secretion factors
(known as paracrine effect), stimulation of preexisting stem cells in the original tissue and
decreasing of inflammation and immune response [72]. Other studies have demonstrated
that MSC-conditioned media by itself could have therapeutic effects. All this data suggest
that MSC apply a reparative effect on injured side through its paracrine effects [73].
It is necessary to overcome some barriers before a cell-based therapy becomes routine in
clinics, including the cell number and the administration way of treatment. MSCs are diffi‐
cult to be maintained stable in culture for long time, but due to their short doubling time, if
at the outset many cells are harvested they may be properly scaled up in primary culture,
never forgetting the ideal seeding number [39].
MSCs are an attractive candidate for cell-based regenerative therapy; the evidence is that
currently there are 139 trial registries for MSC therapy 27 of which are based on umbilical
cord MSCs [74].
3.1. Nerve regeneration
After Central Nervous System (CNS) lesions, Peripheral Nervous System (PNS) injuries are
the ones with minor successes in terms of functional recovery. These kinds of injuries are
frequent in clinical practice. About two centuries ago it was assumed that these nerves
would never regenerate. Indeed, scientific and clinical knowledge greatly increased in this
area. Nevertheless, a full understanding of axonal recovery and treatment of nerve defects,
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especially complete functional achievement and organ reinnervation after nerve injury, still
remains the principle challenge of regenerative biology and medicine [75, 76].
3.1.1. Nerve repair
Many peripheral nerve injuries can only be dealt through reconstructive surgical proce‐
dures. Despite continuous refinement of microsurgery techniques, peripheral nerve repair
still stands as one of the most challenging tasks in neurosurgery, as functional recovery is
rarely satisfactory in these patients [76]. Direct repair should be the procedure of choice
whenever tension-free suturing is possible; however, patients with loss of nerve tissue, re‐
sulting in a nerve gap, are considered for a nerve graft procedure. In these cases, the donor
nerves used for grafting are commonly expendable sensory nerves. This technique, howev‐
er, has some disadvantages, with the most prominent being donor site morbidity, that may
lead to a secondary sensory deficit and occasionally neuroma and pain. In addition, no do‐
nor and recipient nerve diameters often occurs which might be the basis for poor functional
recovery. Alternatives to peripheral nerve grafts include cadaver nerve segments allografts,
end-to-side neurorrhaphy, and entubulation by means of autologous non-nervous tissues,
such as vein and muscles [76]. One advantage of these allografts compared with the auto‐
grafts is the absence of donor site morbidity and theoretically the unlimited length of tissue
available [77]. Experimental work from a number of laboratories has emphasized the impor‐
tance of entubulation for peripheral nerve repair to manage nerve defects that cannot be
bridged without tension (neurotmesis with loss of nerve tissue). Nerves will regenerate from
the proximal nerve stump towards the distal one, whereas neuroma formation and in‐
growth of fibrous tissue into the nerve gap are prevented [78]. The reliability of animal mod‐
els is crucial for PN research, including therapeutic strategies using biomaterials and cellular
systems. As a matter of fact, rodents, particularly the rat and the mouse, have become the
most frequently used animal models for the study of peripheral nerve regeneration because
of the widespread availability of these animals as well as the distribution of their nerve
trunks which is similar to humans [79]. Because of its PN size, the rat sciatic nerve has been
the most commonly experimental model used in studies concerning the PN regeneration
and possible therapeutic approaches [80]. Functional recovery after PN injury is frequently
incomplete, even with adequate microsurgery, so, many research and clinical studies have
been performed including biomaterials for tube-guides. Since the 80’s, Food and Drug Ad‐
ministration (FDA) has approved a variety of these biomaterials both natural and synthetic.
The ideal biomaterial nerve graft should increase number, length and speed of axon regen‐
eration [77]. It should be:
i. biocompatible, not toxic neither present undesired immunologic response;
ii. permeable enough to permit nutrient and oxygen diffusion and allows cell support
systems;
iii. flexible and soft to avoid compression;
iv. biodegradable, the ideal rate is to remain intact during axon regeneration across
nerve gap and after degrade softly and
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v. technically reproducible, transparent, easy to manipulate, and sterilize [81].
Currently 3 types of materials are available for nerve reconstruction: non-resorbable, natural
resorbable and synthetic resorbable. Polyvinil alcohol hydrogel (PVA) is an example of a
non-absorbable biomaterial. It combines water in similar proportions to human tissue, with
PVA providing a stable structure easy to sterilize, which is a main advantage of this materi‐
als, but has some limitations such as: nerve compression and suture tension after regenera‐
tion due to its non-resorbable nature [77]. Collagen type I from humans or animals, is an
example of a natural resorbable device, which has some advantages such as:
i. easy to isolate and purify,
ii. good adhesiveness for supporting cell survival an proliferation,
iii. has been proven to be highly biocompatible and support nerve regeneration in vivo.
On the other hand, offers some immune response requiring the use of immunosuppres‐
sive drugs or pre-treatment of the material before clinical use [77]. Poly (DL-lactide-ε-capro‐
lactone) (PLC) a synthetic resorbable material is the only transparent device approved by
FDA, important characteristic for the surgeon that facilitates the insertion of the nerve stumps
across the nerve gap, but, on the other hand it is not flexible [77]. Chitosan, PLC, colla‐
gen, poly(L-lactide) and poly(glycolide) copolymers (PLGA) and others, some of them, pre‐
viously studied by our group [57, 58, 82] were associated to cellular systems, which are able
to differentiate into neuroglial-like cells or capable of modulating the inflammatory proc‐
ess, improved nerve regeneration, in terms of motor and sensory recovery, and also shorten‐
ing the healing period after axonotmesis and neurotmesis, avoiding regional muscular
atrophy [57, 58, 82].
Researches with acellular nerve allografts, as alternative for repairing peripheral nerve de‐
fects have been reported. These nerve allografts remove the immunoreactive SCs and mye‐
lin however preserve the internal structure of original nerve, containing vital components such
as collagen I, laminin and growth factors essential for repairmen of the lesions [83]. Acellu‐
lar grafts remain insufficient, due to the increasing extent of nerve damages. Also, viable cells
are necessary for debris removal and environmental regeneration reestablishment [83].
Cell transplantation, such as Schwann cells (SCs) transplantation has been proposed as a
method of improving peripheral nerve regeneration [84]. SCs are peripheral glial cells that
enwrap axons to form myelin with a central role in neuronal function. When there is dam‐
age in PNS, SCs are induced to mislay myelin, proliferate and segregate numerous factors,
including cytokines responsible for reproducing a microenvironment suitable for support‐
ing axon regeneration [85, 86]. They also have a vital participation in endogenous repair, re‐
constructing myelin, which are essential for functional recovery [85, 86]. SCs, MSCs, ESCs,
marrow stromal cells are the most studied support cells candidates. SCs transplantation en‐
hance axon outgrowth both in vitro [87] and in vivo [88]. Although to achieve an adequate
amount of autologous SC, a donor nerve is necessary and a minimum of 4-8 weeks for in
vitro expansion. Umbilical cord MSCs may be the perfect cell model as supplement for nerve
grafts, once they are easily obtained, with no ethical controversy and can differentiate into
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neuglial-like cells [83]. Matuse and collaborators induced MSCs from the umbilical cord into
SCs capable of supporting peripheral nerve regeneration and myelin reconstruction in vivo.
They transplanted these SCs into injured sciatic nerve, and proved that these cells main‐
tained their differentiated phenotype in vivo, and contributed for axonal regeneration and
functional recovery [89].
In our studies we aimed to explore the therapeutic value of human umbilical cord matrix
(Wharton’s jelly) derived MSCs, undifferentiated and differentiated in neuroglial-like cells,
both in vitro and in vivo, associated to a variety of biomaterials such as, Poly (DL-lactide-ε-
caprolactone) PLC (Vivosorb®) membrane, and Chitosan type III on rat sciatic nerve axo‐
notmesis and neurotmesis experimental model. For cell transplantation into injured nerves
(with axonotmesis and neurotmesis injuries), there are two main techniques. The cellular
system may be directly inoculated into the neural scaffold which has been interposed be‐
tween the proximal and distal nerve stumps or around the crush injury (in neurotmesis and
axonotmesis injuries, respectively); or the cells can be pre-added to the neural scaffold via
inoculation or co-culture (in most of the cellular systems, it is allowed to form a monolayer)
and then the biomaterial with the cellular system is implanted in the injured nerve [82].
Our PLC studies [55] demonstrated that this biomaterial does not interfere negatively with
the nerve regeneration process, in fact, the information on the effectiveness of PLC mem‐
branes and tube-guides for allowing nerve regeneration was already provided experimen‐
tally and with patients [82]. PLC becomes hydrophilic by water uptake, which increases the
permeability of the polymer. This is essential for the control of nutrient and other metabolite
transportation to the surrounding healing tissue. A few weeks after implantation, the me‐
chanical power gradually decreases and there is a loss of molecular weight as a result of the
hydrolysis process. Nearly in 24 months, PLC degrades into lactic acid and hydroxycaproic
acid which are both safely metabolized into water and carbon dioxide and/or excreted
through the urinary tract. In contrast to other biodegradable polymers, PCL has the advant‐
age of not creating an acidic and potentially disturbing micro-environment, which is favora‐
ble to the surrounding tissue [90]. Chitosan has attracted particular attention in medical
areas due to its biocompatibility, biodegradability, and low toxicity, low cost, improvement
of wound-healing and antibacterial properties. Moreover, the potential use of chitosan in
nerve regeneration has been demonstrated both in vitro and in vivo [57, 91]. Chitosan is a
partially deacetylated polymer of acetyl glucosamine obtained after the alkaline deacetyla‐
tion of chitin [57, 82]. While chitosan matrices have low mechanical strength under physio‐
logical conditions and are unable to maintain a predefined shape after transplantation, their
mechanical properties can be improved by modification with a silane agent, namely γ-glyci‐
doxypropyltrimethoxysilane (GPTMS), one of the silane-coupling agents which has epoxy
and methoxysilane groups. The epoxy group reacts with the amino groups of chitosan mole‐
cules, while the methoxysilane groups are hydrolyzed and form silanol groups. Finally, the
silanol groups are subjected to the construction of a siloxane network due to the condensa‐
tion. Thus, the mechanical strength of chitosan can be improved by the cross-linking be‐
tween chitosan, GPTMS and siloxane network. By adding GPTMS and employing a freeze-
drying technique, we have previously obtained chitosan type III membranes (hybrid
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chitosan membranes) with pores of about 110 μm diameter and about 90% of porosity, and
which were successful in improving sciatic nerve regeneration after axonotmesis and neuro‐
tmesis [56, 57, 82].
The induction of a crush injury in rat sciatic nerve provides a very realistic and useful model
of damage for the study of the role of numerous factors in regenerative processes [57]. Focal
crush causes axonal interruption but preserves the connective sheaths (axonotmesis). After
axonotmesis injury regeneration is usually successful, after a short (1-2 day) latency, axons
regenerate at a steady rate towards the distal nerve stump, supported by the reactive SCs
and the preserved endoneural tubules enhance axonal elongation and facilitate adequate re‐
innervation [92]. Our research group has been testing the efficacy of combining biomaterials
and cellular systems in the treatment of sciatic nerve crush injury [57-59, 82, 90, 91, 93-95].
Following transection, axons show staggered regeneration and may take substantial time to
actually cross the injury site and enter the distal nerve stump [60]. Although delayed axonal
elongation might be caused by growth inhibition originating from the distal nerve itself,
growth-stimulating influences may overcome axons stagger. More robust and fast nerve re‐
generation is expected to result in better reinnervation and functional recovery. As a poten‐
tial source of growth promoting signals, MSCs transplantation is expected to have a positive
outcome. Our results showed that the use of either undifferentiated or differentiated
HMSCs enhanced the recovery of sensory and motor function in axonotmesis lesion of the
rat sciatic nerve [56]. Neurotmesis must be surgically treated by direct end-to-end suture of
the two nerve stumps or by a nerve graft harvested from elsewhere in the body in case of
tissue loss. To avoid secondary damage due to harvesting of the nerve graft, a tube-guide
can be used to bridge the nerve gap. Acutely after sciatic nerve transection there is a com‐
plete loss of both motor and thermal sensory function. Sensory and motor deficit then pro‐
gressively decrease along the post-operative. From a morphological point of view, nerve
regeneration occurs if Wallerian degeneration is efficient and is substituted by re-growing
axons and the accompanying viable SCs [96, 97]. The axon regeneration pattern is improved
by using appropriate biomaterials for the tube-guide design, like chitosan type III and PLC
and cellular systems like MSCs from the Wharton jelly [57, 90, 91, 95]. The surgical techni‐
que and the time for the reconstructive surgery is also crucial for the nerve regeneration af‐
ter neurotmesis [57, 90, 91, 95].
3.2. Assessment of nerve regeneration in the sciatic nerve rat model
Although both morphological and functional data have been used to assess neural regenera‐
tion after induced crush injuries, the correlation between these two types of assessment is
usually poor [94, 98-100]. Classical and newly developed methods of assessing nerve recov‐
ery, including histomorphometry, retrograde transport of horseradish peroxidase and retro‐
grade fluorescent labeling [79] do not necessarily predict the reestablishment of motor and
sensory functions [100-103]. Although such techniques are useful in studying the nerve re‐
generation process, they generally fail in assessing functional recovery [100]. In this sense,
research on peripheral nerve injury needs to combine both functional and morphological as‐
sessment. The use of biomechanical techniques and rat’s gait kinematic evaluation is a prog‐
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ress in documenting functional recovery [104]. Indeed, the use of biomechanical parameters
has given valuable insight into the effects of the sciatic denervation/reinnervation, and thus
represents an integration of the neural control acting on the ankle and foot muscles, which is
very useful and accurate to evaluate different therapeutic approaches [103-105].
3.2.1. Functional Assessment
After injury and treatment of animals, follow-up results are very important for analysis of
functional recovery. Animals are tested preoperatively (week 0), and every week during 12
and 20 weeks, for axonotmesis and neurotmesis of the rat sciatic nerve, respectively. Motor
performance and nociceptive function are evaluated by measuring extensor postural thrust
(EPT) and withdrawal reflex latency (WRL), respectively [55, 58, 94]. For EPT test, the affect‐
ed and normal limbs are tested 3 times, with an interval of 2 minutes between consecutive
tests, and the 3 values are averaged to obtain a final result. The normal (unaffected limb)
EPT (NEPT) and experimental EPT (EEPT) values are incorporated into an equation (Equa‐
tion (1)) to derive the percentage of functional deficit, as described in the literature [106]:
( )% Motor deficit  NEPT –  EEPT  /  NEPT   100= ´é ùë û (1)
The nociceptive withdrawal reflex (WRL) was adapted from the hotplate test developed by
Masters et al. [107]. Normal rats withdraw their paws from the hotplate within 4s or less.
The cutoff time for heat stimulation is set at 12 seconds to avoid skin damage to the foot.
For Sciatic Functional Index (SFI), animals are tested in a confined walkway that they cross,
measuring 42 cm long and 8.2 cm wide, with a dark shelter at the end. Several measure‐
ments are taken from the footprints:
i. distance from the heel to the third toe, the print length (PL);
ii. distance from the first to the fifth toe, the toe spread (TS); and
iii. distance from the second to the fourth toe, the intermediary toe spread (ITS).
In the static evaluation (SSI) only the parameters TS and ITS, are measured. For SFI and SSI,
all measurements are taken from the experimental (E) and normal (N) sides. Prints for meas‐
urements are chosen at the time of walking based on precise, clear and completeness of foot‐
prints. The mean distances of three measurements are used to calculate the following factors
(dynamic and static):
( ) ( )Toe spread factor TSF   ETS –  NTS  /  NTS= (2)
( ) ( )Intermediate toe spread factor ITSF   EITS –  NITS  /  NITS= (3)
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( ) ( )Print length factor PLF   EPL  NPL  /  NPL= - (4)
SFI is calculated as described by Bain et al. [108] according to the following equation:
( ) ( ) ( )
( ) ( ) ( )
SFI  38.3 EPL –  NPL  /  NPL  109.5 ETS –  NTS  /  NTS  13.3 EIT –  NIT  /  NIT –  8.8
 38.3  PLF   109.5  TSF   13.3  ITSF  –  8.8
= - + +
= - ´ + ´ + ´ (5)
For SFI and SSI, an index score of 0 is considered normal and an index of -100 indicates total
impairment. When no footprints are measurable, the index score of -100 is given [109]. In
each walking track 3 footprints are analyzed by a single observer, and the average of the
measurements is used in SFI calculations.
Ankle kinematics analysis is carried out prior nerve injury, at week-2 and every 4 weeks
during the 12 or the 20-week follow-up time, for axonotmesis and neurotmesis lesions, re‐
spectively. The motion capture is performed with 2 digital high speed cameras (Oqus, Qual‐
ysis®) at a rate of 200 images per second, and Qualisys Track Manager software (QTM,
Qualysis®). The cameras operate on a infra-red light frequency ensuring a high level of ac‐
curacy on the determination of reflective marker position and a position residual of less than
2.7 mm was obtained. Cameras are usually positioned to not recorder significant signal de‐
flection during the test and four reflective markers were placed at the skin of the rat right
hindlimb at the proximal edge of the tibia, the lateral malleolus and the fifth metatarsal
head. Advanced analysis of the 2-D movement (sagittal plan) data is performed with Visu‐
al3D software (C-Motion®, Inc). The rats’ ankle angle is determined using the scalar product
between a vector representing the foot and a vector representing the lower leg. With this
model, positive and negative values of position of the ankle joint (θ°) indicate dorsiflexion
and plantarflexion, respectively. For each step cycle the following time points are identified:
midswing, midstance, initial contact (IC) and toe-off (TO) [104, 109-113] and are time nor‐
malized for 100% of step cycle. The normalized temporal parameters are averaged over all
recorded trials. Angular velocity of the ankle joint (Ω °/s) is also determined where negative
values correspond to dorsiflexion. A total of 6 walking trials for each animal with stance
phases lasting between 150 and 400 ms are considered for analysis, since this corresponds to
the normal walking velocity of the rat (20–60 cm/s) [104]. Animals walk on a Perspex track
with length, width and height of respectively 120, 12, and 15 cm. In order to ensure locomo‐
tion in a straight direction, the width of the apparatus is adjusted to the size of the rats dur‐
ing the experiments.
3.2.2. Morphologic Assessment
Nerve samples are processed for quantitative morphometry of myelinated nerve fibers
[114]. Fixation is usually carried out using 2.5% purified glutaraldehyde and 0.5% saccarose
in 0.1M Sorensen phosphate buffer for 6-8 hours and resin embedding is obtained following
Glauerts' procedure (Scipio et al., 2008). Series of 2-μm thick semi-thin transverse sections
are cut using a Leica Ultracut UCT ultramicrotome (Leica Microsystems, Wetzlar, Germany)
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and stained by Toluidine blue. Stereology is carried out on a DM4000B microscope equip‐
ped with a DFC320 digital camera and an IM50 image manager system (Leica Microsystems,
Wetzlar, Germany). Systematic random sampling and D-disector is always adopted using a
protocol previously described [115, 116]. Fiber density and total number of myelinated fi‐
bers is estimated together with fiber and axon diameter and myelin thickness.
3.3. Results
3.3.1. Differentiation and metabolism of MSCs from Wharton’s jelly
In our experimental studies we expanded undifferentiated MSCs from human umbilical
cord Wharton’s jelly that exhibited a normal star-like shape with a flat morphology in cul‐
ture (Figures 4 and 5). To prevent the possibility of eventual mutations due to expansion ar‐
tifacts, a total of 20 Giemsa-stained metaphases of these cells, were analyzed for numerical
aberrations. Sporadic, non-clonal aneuploidy was found in 3 cells (41-45 chromosomes). The
other 17 metaphases had 46 chromosomes (Figure 7). The karyotype was determined in a
completely analyzed G-banding metaphase. No structural alterations were found. The kar‐
yotype analysis to the MSCs cell line derived from Human Wharton jelly demonstrated that
this cell line has not neoplastic characteristics and is stable during the cell culture proce‐
dures in terms of number and structure of the somatic and sexual chromosomes [55].
Figure 7. Selected metaphases from undifferentiated MSC cells isolated from Wharton’s jelly, showing the normal
number of chromosomes (46, XY). Magnification: 1000X.
We differentiated MSC from Wharton’s Jelly into neuroglial-like cells. After 96 hours of in‐
cubation in neurogenic medium, we observed a morphological change. The cells became ex‐
ceedingly long and there was a formation of typical neural-like cells with multi-branches
and secondary branches (Figure 6). The differentiation was tested based on the expression of
typical neuronal markers such as GFAP, GAP-43 and NeuN by neural-like cells attained
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from HwMSCs. Undifferentiated MSCs were negatively labeled to GFAP, GAP-43 and
NeuN (Figure 8A,C,E). After 96 hours of differentiation the attained cells were positively
stained for glial protein GFAP (Figure 8B) and for the growth-associated protein GAP-43
(Figure 8D). All nucleus of neural-like cells were also labeled with the neuron specific nucle‐
ar protein called NeuN (Figure 8F) showing that differentiation of MSCs in neural-like cells
were successfully achieved [55].
Figure 8. Undifferentiated MSC cells from the Wharton’s jelly presenting a negative staining for: (A) GFAP which is a
glial cell marker; (C) GAP-43 which is related with axonal outgrowth and (E) NeuN which is a marker for nucleus of
neurons. Neuroglial-like cells obtained from HMSCs in vitro differentiated with neurogenic medium exhibiting a posi‐
tive staining for: (B) GFAP; (D) GAP-43 and (F) NeuN. Magnification: 200x [55].
The in vitro expansion and differentiation of MSCs for clinical cell-based therapy is a very
expensive and long process that needs standardization. Although pre-clinical and clinical
data demonstrated the safety and effectiveness of MSCs therapy in some pathologies such as
neurological, there are still questions surrounding the mechanism of action. In our research
work we aimed to disclose the possible role of metabolism not only in the MSCs mainte‐
nance and expansion but also during the differentiation in neural-like cells [55]. MSCs main‐
tenance and differentiation, to neural-like cells, depends on metabolic modulation. In vitro,
glucose is the most widely used substrate for the generation ATP which is essential for cell
growth and maintenance. It has been proposed that cells undergoing high proliferation rates
depend on glycolysis to generate ATP, known as Warburg effect, although this pathway is
less effective than the oxidative phosphorylation in terms of ATP production [117]. Our re‐
sults showed that during expansion, the undifferentiated MSCs consume glucose and pro‐
duce high concentration of lactate as a metabolic sub product which is consistent with the
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Warburg effect and glycolysis stimulation. MSCs do not require oxidative phosphorylation
to survive as alternative, hypoxia extends the lifespan, increases their proliferative ability
and reduces differentiation [118]. The morphologic and biochemical characteristics of neu‐
ral-like cells are already described but the mechanism by which stem cells differentiate into
neural-like cells is still unknown. In our research work, MSCs that undergone differentiation
into neural-like cells, consumed significantly less glucose and produced significantly less
lactate than MSCs that undergone only expansion. These major differences allow us to con‐
clude that during MSCs differentiation in neural-like cells the glycolytic process, which
proved to be the crucial metabolic mechanism during MSCs expansion, is switched to oxida‐
tive metabolism [55].
Our results show clear evidences that MSCs expansion is dependent of glycolysis while
their differentiation in neural-like cells requires the switch of the metabolic profile to oxida‐
tive metabolism. Also important may be the role of oxidative stress during this process. This
work is a first step to identify key metabolic-related mechanisms responsible for human
MSCs from the Wharton’s jelly expansion and differentiation [55].
The lack of standardization of MSCs isolated from the Wharton’s jelly culture conditions has
limited some progress in scientific and clinical research. Understanding these MSCs metabo‐
lism during expansion, as well as determining molecular and biochemical mechanisms for
differentiation is of great significance to develop new effective stem cell-based therapies.
4. Biomaterial and cellular system association – discussion and final
remarks
Using the rat model, we recently tested in vivo the efficacy of biomaterials and cellular sys‐
tem association in treatment of sciatic nerve axonotmesis and neurotmesis injury. Following
transection, axons show staggered regeneration and may take substantial time to cross the
injured site and enter the distal nerve stump [119]. However delayed axonal elongation
might be caused by growth inhibition originated from the distal nerve itself, growth-stimu‐
lating influences may overcome axons stagger. As a potential source of growth promoting
signals, MSCs transplantation is expected to give a positive outcome. Our results showed
that the use of either undifferentiated or differentiated MSCs in axonotmesis lesion boosted
the recovery of sensory and motor function. In both cell-enriched experimental groups we
observed that the myelin sheath was thicker, this suggests that MSCs might apply their posi‐
tive effects on SCs, the key element in Wallerian degeneration and the following axonal re‐
generation [120]. Also results from in vivo testing previously performed by our research
group showed that infiltration of MSCs from the Wharton’s jelly, or the combination of chi‐
tosan type III membrane enwrapment and MSCs enrichment after nerve crush injury pro‐
vide an advantage to post-traumatic nerve regeneration [56, 57]. Chitosan type III was
developed as a hybrid of chitosan by adding GPTMS. A synergistic effect of an extra perme‐
ability and physicochemical properties of chitosan type III and the presence of silica ions
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may be responsible for the good results in post-traumatic nerve regeneration promotion ob‐
served in the sciatic nerve after axonotmesis and neurotmesis [57, 91]. The substantial im‐
provement of axonal regeneration found in sciatic nerve crush enwrapped by chitosan type
III membranes and for bridging nerve gaps after neurotmesis [57, 91], suggests that this bio‐
material may not just work as a simple mechanical device but instead may induce nerve re‐
generation. The neuroregenerative properties of chitosan type III may be explained by the
effect on SCs proliferation, axon elongation and myelinization [55, 91]. Our data also
showed that PLC does not deleteriously interfere with the nerve regeneration process, as a
matter of fact, the information on the effectiveness of PLC membranes and tube-guides for
allowing nerve regeneration was already provided experimentally and with patients [82].
The MSCs from the Wharton’s jelly may be a valuable source in the repair of the peripheral
nervous system with capacity to differentiate into neuroglial-like cells. The transplanted
MSCs are also able to promote local blood vessel formation and release the neurotrophic fac‐
tors brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor
(GDNF) [55]. Previous results obtained by our research group using N1E-115 cells in vitro
differentiated into neuroglial-like cells to promote regeneration of axonotmesis and neuro‐
tmesis lesions in the rat model showed that there was no significant effect in promoting ax‐
on regeneration and, when N1E-115 cells were cultured inside a PLGA scaffold used to
bridge a nerve defect, they can even exert negative effects on nerve fiber regeneration. The
presence of transplanted N1E-115 cells in nerve scaffolds competing for the local blood sup‐
ply of nutrients and oxygen and by space-occupying effect could have hindered the positive
effect of local neurotrophic factor release leading a negative outcome on nerve regeneration.
Thus, N1E-115 cells did not prove to be a suitable candidate cellular system for treatment of
nerve injury after axonotmesis and neurotmesis and their application is limited only to re‐
search purposes as a basic scientific step for the development of other cell delivery systems,
due to its neoplastic origin [57-59, 91, 93]. The MSCs isolated from the Wharton´s jelly
through PLC and chitosan type III membranes might be a potentially valuable tool to im‐
prove clinical outcome especially after trauma to sensory nerves, such as digital nerves. The
results from our experimental work [55, 56] showed that the use of either undifferentiated or
neuroglial-like differentiated MSCs enhanced the recovery of sensory and motor function of
the rat sciatic nerve. The observation that in both cell-enriched experimental groups myelin
sheath was thicker, suggest that MSCs might exert their positive effects on SCs, the key ele‐
ment in Wallerian degeneration and the following axonal regeneration [120]. In addition,
these cells represent a non-controversial source of primitive mesenchymal progenitor cells
that can be harvested after birth, cryogenically stored, thawed, and expanded for therapeu‐
tic uses, including nerve injuries like axonotmesis and neurotmesis. The time and tempera‐
ture of the transport (and the saline solution used) of the UC units from the hospital / clinic
to the laboratory is crucial for a successful outcome considering MSCs isolation and prolifer‐
ation from fresh and cryopreserved UCT. It is highly recommend that the transport from the
clinic or hospital to the laboratory should be refrigerated, and the UC units should be imme‐
diately immersed in a sterile saline solution like HBSS or DPBS.
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